Summary: Aetna, a CVS Health company, modified CPB 1082 covering follitropins and menotropins, effective April 11, 2026. Here's what billing teams need to do.
Aetna updated its follitropin and menotropin coverage policy under CPB 1082. This policy governs injectable gonadotropins used in infertility treatment — including controlled ovarian stimulation and assisted reproductive technology (ART) protocols. The full policy document does not list specific CPT or HCPCS codes in the data provided here. Billing teams who handle reproductive endocrinology, OB/GYN, or fertility clinic accounts should review CPB 1082 Aetna directly before April 11, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Follitropins and Menotropins – CPB 1082 |
| Policy Code | CPB 1082 |
| Change Type | Modified |
| Effective Date | April 11, 2026 |
| Impact Level | High |
| Specialties Affected | Reproductive Endocrinology, OB/GYN, Fertility Clinics, Pharmacy Billing |
| Key Action | Review updated medical necessity criteria and prior authorization requirements for follitropin and menotropin claims before April 11, 2026 |
Aetna Follitropins and Menotropins Coverage Criteria and Medical Necessity Requirements 2026
The Aetna follitropin and menotropin coverage policy under CPB 1082 governs one of the most claim-sensitive areas in reproductive medicine. Follitropins (FSH analogs like follitropin alfa and follitropin beta) and menotropins (combined FSH/LH preparations like human menopausal gonadotropin, or hMG) are expensive injectable drugs. They're also among the most frequently denied when documentation falls short.
Aetna modified this policy on April 11, 2026. The specific wording of the changes isn't available in the public data extract, but any modification to CPB 1082 typically touches medical necessity thresholds, covered diagnoses, step therapy requirements, or prior authorization workflows. All of these directly affect your claim approval rate.
For follitropins and menotropins billing, medical necessity documentation is the core issue. Aetna's policies in this category historically require documented infertility diagnosis, prior treatment failure (such as clomiphene citrate trials where applicable), and physician-supervised protocols. If the April 2026 revision tightened any of these requirements, claims submitted without updated supporting documentation will generate denials.
Prior authorization is standard for this drug class across most Aetna commercial plans. If the modification changed prior auth criteria — either the clinical thresholds that trigger approval or the documentation required to support a request — your prior auth team needs to know before the effective date. A prior auth approved under the old criteria may not align with post-April 11 requirements if it's submitted or renewed after the change goes live.
Medical necessity criteria for gonadotropins typically cover:
| # | Covered Indication |
|---|---|
| 1 | Anovulatory infertility where oral agents have failed or are contraindicated |
| 2 | Controlled ovarian stimulation (COS) as part of IUI or ART protocols |
| 3 | Hypogonadotropic hypogonadism in male or female patients |
| 4 | Superovulation induction in conjunction with ART |
Reimbursement for these drugs runs through either the medical benefit (for office-administered injectable medications billed under the J-code category) or the pharmacy benefit (for self-administered injectables). Which benefit applies depends on the specific plan and how the drug is dispensed. This distinction matters because CPB 1082 may apply differently depending on which benefit pathway you're billing.
If you're not sure how the April 2026 revision applies to your patient population or plan mix, talk to your compliance officer before the effective date.
Aetna Follitropins and Menotropins Exclusions and Non-Covered Indications
Aetna's gonadotropin coverage policies have historically excluded several categories. While the specific exclusions in the April 11, 2026 version of CPB 1082 aren't available in the policy data extract, billing teams should know the patterns that commonly generate claim denial in this category.
Plans without infertility riders. Many Aetna commercial plans don't include infertility benefits at all. CPB 1082 coverage criteria only apply when the member's plan includes infertility coverage. Verify the member's benefit structure before submitting a prior auth request or a claim.
Cosmetic or non-medical use. Gonadotropins used for purposes outside of documented infertility treatment or hypogonadism — including some weight loss protocols or off-label indications — are not covered under standard medical necessity criteria.
Insufficient documentation of prior treatment failure. In most ART and COS protocols, Aetna requires evidence that less intensive treatments were tried first. Claims that skip this documentation trail get denied even when the patient is clinically appropriate for gonadotropins.
Male infertility without documented hypogonadotropic hypogonadism. Use in male patients carries stricter criteria. Document the hormonal diagnosis, not just the infertility finding.
Check the full CPB 1082 text at the Aetna source before assuming prior exclusions still apply unchanged. The April 11, 2026 modification may have narrowed or expanded the excluded indications list.
Coverage Indications at a Glance
Because the specific policy data extract for CPB 1082 doesn't include a line-by-line breakdown of covered versus non-covered indications, the table below reflects the standard coverage framework for Aetna gonadotropin policies. Verify each row against the current CPB 1082 text before relying on it for billing decisions.
| Indication | Status | Notes |
|---|---|---|
| Anovulatory infertility (prior oral agent failure) | Covered (plan-dependent) | Prior authorization required; document clomiphene trial where applicable |
| Controlled ovarian stimulation for IUI | Covered (plan-dependent) | Prior auth required; infertility rider must be active on member's plan |
| Controlled ovarian stimulation for IVF/ART | Covered (plan-dependent) | Prior auth required; ART benefit must be present |
| Hypogonadotropic hypogonadism (female) | Covered | Medical necessity documentation must include hormonal workup |
| Hypogonadotropic hypogonadism (male) | Covered with criteria | Documented FSH/LH deficiency required; not covered for idiopathic male infertility without hormonal diagnosis |
| Plans without infertility rider | Not Covered | Verify benefit structure before submitting |
| Off-label / non-infertility indications | Not Covered / Investigational | Case-by-case; not covered under standard CPB 1082 criteria |
Aetna Follitropins and Menotropins Billing Guidelines and Action Items 2026
The April 11, 2026 effective date is your hard deadline. Here's what your billing and prior auth teams should do before then.
| # | Action Item |
|---|---|
| 1 | Pull the current CPB 1082 text from Aetna's website and compare it to the previous version. The policy data available here doesn't include the specific line-by-line changes. You need the actual document. Go to the Aetna Clinical Policy Bulletins page and find CPB 1082 directly, or use the PayerPolicy version diff tool to see exactly what changed. |
| 2 | Audit your prior authorization queue for any active or pending gonadotropin auths. If you have prior auths approved before April 11 that extend past that date, determine whether the approval criteria still align with the modified policy. Auths approved under the old criteria may create problems at claims adjudication if the coverage policy has shifted. |
| 3 | Update your patient intake documentation templates. If CPB 1082 now requires different or additional clinical documentation for medical necessity — updated diagnosis criteria, new step therapy requirements, or revised hormonal threshold documentation — your intake forms need to reflect that before you submit your first post-April-11 claim. |
| 4 | Verify infertility rider status on every member before submitting claims. This is always best practice for fertility billing, but any policy modification is a good trigger to re-check your eligibility verification workflow. A claim denial on a member without an infertility rider isn't a coding error — it's a benefits verification miss. |
| 5 | Confirm which benefit pathway applies — medical or pharmacy. Follitropins and menotropins billed through the medical benefit use J-codes and are subject to CPB 1082 through the medical claims pathway. Drugs dispensed through specialty pharmacy and billed under the pharmacy benefit follow a different adjudication route. Know which pathway each of your patient cases uses. |
| 6 | Check for any changes to step therapy or formulary requirements. Aetna sometimes requires specific gonadotropin formulations before others — for example, requiring a biosimilar follitropin before a branded product. If the April 2026 modification updated step therapy requirements, your prescribers need to know before they submit orders. |
| 7 | Contact your Aetna provider relations representative if the policy language is ambiguous. When a modification changes coverage criteria in a way that doesn't clearly apply to your patient population or service mix, don't guess. Get written confirmation of how Aetna interprets the updated criteria. That documentation protects you in an appeal. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Follitropins and Menotropins Under CPB 1082
The policy data provided for this update does not include specific CPT, HCPCS, or ICD-10 codes. Do not rely on this post alone for code selection.
For follitropins and menotropins billing, the relevant codes typically fall in the HCPCS J-code range for injectable drugs administered in a clinical setting, as well as procedure codes for monitoring services associated with gonadotropin stimulation cycles. ICD-10 diagnosis codes in the N97.x (female infertility) and E23.x (hypofunction of pituitary gland, including hypogonadotropic hypogonadism) families are commonly associated with these drugs.
Pull the full CPB 1082 document from Aetna directly to confirm which codes the updated policy references. The source URL for this policy is: https://app.payerpolicy.org/p/aetna/1082
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.